Traditionally, the main model of the pharmaceutical industry for developing new drugs has been based on monotherapies, new molecular entities (NMEs), and their underlying one-target-one-disease dogma. It is no surprise that closely related fields such as the cosmeceutical and nut...
Open access
Research Article10.9734/BJMMR/2016/18997
Several drugs have been shown to facilitate locomotor rhythmogenesis and treadmill training after Spinal Cord Injury (SCI). Clonidine, an alpha-adrenoceptor agonist, is of particular interest given its well-known effects on facilitation of reflex-induced spinal stepping in acute...
Open access
Research Article10.9734/BJMMR/2016/19057
No cure or acceptable treatment exists against bladder problems and urinary retention in spinal cord-injured (SCI) patients. Although some non-central nervous system (CNS)-acting drugs exist, as symptomatic treatment, most have been associated with significant side effects and de...
Open access
Research Article10.9734/BJMMR/2016/19011
No cure and no safe or acceptable treatment exist yet against bowel problems and chronic constipation in spinal cord-injured (SCI) patients. Although some non-central nervous system (CNS)-acting drugs have already been identified and used clinically as symptomatic treatment, most...
Open access
Research Article10.9734/BJMMR/2016/19033